Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

About NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office is the TTIPO that assists partnering with the NIAID.

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebo...

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

Contact NIAID Technology Transfer and Intellectual Property Office

Phone Number
301-496-2644

More About NIAID Technology Transfer and Intellectual Property Office

Therapeutic Areas
  • Autoimmune disorders
  • Infectious
  • Inflammation
Technologies
  • Antimicrobial
  • Biologics
  • Diagnostics
  • Nucleic acids
  • Peptides
  • Small molecules
  • Vaccines
Company Type
  • Public/Non-profit organisation
State of Ownership
  • Public
Sponsor content

Collaborative Research and Licensing Opportunity for a Research Material: A Potent, Broadly-neutralizing, Anti-HIV Antibody (35O22) that Binds a Novel Epitope

35O22 is a potent anti-HIV antibody that binds a novel HIV epitope. This antibody neutralizes at least 80% of HIV isolates tested so far. The unique binding of 35O22 makes it an attractive candidate to combine with other HIV antibodies or antivirals in treating or preventing HIV infection.
Sponsor content

Collaborative Research and Licensing Opportunity: HIV targets CD62L on central memory T cells through viral envelope glycans for adhesion and induces selectin shedding for viral release

NIAID researchers have shown that inhibition of CD62L shedding dramatically reduced HIV-1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.
Sponsor content

Collaborative Research and Licensing Opportunity: Broadly Neutralizing Antibodies against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy.
Sponsor content

A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine

This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin.
Sponsor content

Collaborative Research and Licensing Opportunity: Inhibition of host heme oxygenase-1 as an adjunctive treatment to improve the outcome of conventional antibiotic chemotherapy of Mycobacterium tuberculosis (Mtb) infection.

Inhibition of host HO-1 reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control.
Sponsor content

Collaborative Research and Licensing Opportunity: Zika Virus Vaccines

Scientists at NIAID have developed nucleic acid-based vaccine candidates to prevent ZIKV infection in humans. The current lead candidate vaccine is a plasmid DNA vaccine demonstrated to accord protection in preclinical models and is undergoing clinical trial evaluation.Immunization with the nucleic acid ZIKV vaccine candidate results in production of noninfectious virus like particles (VLPs) made of ZIKV proteins.These ZIKV VLPs elicit an immune response which includes neutralizing antibodies to ZIKV.
Sponsor content

Collaborative Research and Licensing Opportunity: A bivalent conjugate vaccine for Malaria and Typhoid prophylaxis

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response against Salmonella typhi Vi polysaccharide (ViP).